Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 20   

Articles published

APRI 2.38 -0.02 (-0.83%)
price chart
Apricus Biosciences' Partner in the United Kingdom Accepts First Shipment of ...
SAN DIEGO, April 16, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that Takeda ...
Related articles »  
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9%
Apricus Biosciences, Inc. (APRI - Snapshot Report) was a big mover last session, as the company saw its shares rise almost 19% on the day.
Related articles »  
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the ...
Apricus Biosciences, Inc. ( APRI ) was a big mover last session, as the company saw its shares rise almost 19% on the day.
Related articles »  
Eye Catching Stocks: Apricus Biosciences Inc (APRI), Akebia Therapeutics Inc ...
Apricus Biosciences Inc (NASDAQ:APRI) shares jumped more than 17 percent today after the pharmaceutical company announced national phase sanction for its Vitaros treatment in Luxembourg.
Apricus Has Begun The Successful Launch Of Vitaros
Richard Pascoe, Chief Executive Officer of Apricus, commented, "We are excited to have completed the first of several product shipments of Vitaros� to different territories in Europe this year.
Stocks Breaking Out: Zogenix (ZGNX), Apricus Biosciences (APRI), Interactive ...  Street Register
Unusual Volume at NASDAQ: Advent Software (NASDAQ:ADVS), China XD ...  Gaining Green
Related articles »  
Apricus Biosciences and Its European Partners to Sponsor Symposium on ...
SAN DIEGO, April 7, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the ...
Related articles »  
Apricus Biosciences Announces National Phase Approval for Vitaros in ...
Apricus Biosciences, Inc. (Nasdaq: APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Ministry of Health of Luxembourg has granted national ...
Apricus Biosciences Announces National Phase Approval for Vitaros(R) in ...  Wall Street Journal
Related articles »  
Drug Manufacturers Most Active: Prana Biotechnology (NASDAQ:PRAN ...
Apricus Biosciences Inc (NASDAQ:APRI) was a big mover last session, as the company saw its shares rise almost 19% on the day.
Related articles »  
Apricus Biosciences' ED drug, Vitaros receives Luxembourg approval
... launches in their respective territories with product launches expected throughout 2014. Apricus Biosciences, Inc. (APRI) is a pharmaceutical company focused on the development and commercialization of novel therapeutics for men's and women's health.
Eye-Catching Stocks � Zalicus, (NASDAQ: ZLCS), Zogenix, (NASDAQ: ZGNX ...
Apricus Biosciences Inc (NASDAQ:APRI) reported 1.22 million shares were exchanged during the last trade, while the average volume is about 245,744 shares.
Unusual 11 Mid-Day Movers 04/16: (ZLCS) (AKBA) (IMGN) Higher; (XGTI) (AEM ...  StreetInsider.com (subscription)
Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc ...  Galaxy Stocks
Related articles »